Identification of a gene expression signature associated with breast cancer survival and risk that improves clinical genomic platforms

Santiago Bueno-Fortes; Alberto Berral-Gonzalez; José Manuel Sánchez-Santos; Manuel Martin-Merino; Javier De Las Rivas

doi:10.1093/bioadv/vbad037

Identification of a gene expression signature associated with breast cancer survival and risk that improves clinical genomic platforms

Bioinform Adv. 2023 Mar 22;3(1):vbad037. doi: 10.1093/bioadv/vbad037. eCollection 2023.

Authors

Santiago Bueno-Fortes¹, Alberto Berral-Gonzalez¹, José Manuel Sánchez-Santos², Manuel Martin-Merino³, Javier De Las Rivas¹

Affiliations

¹ Cancer Research Center (CiC-IMBCC, CSIC/USAL and IBSAL), Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca 37007, Spain.
² Department of Statistics, University of Salamanca (USAL), Salamanca 37008, Spain.
³ Department of Computer Science, Universidad Pontificia de Salamanca (UPSA), Salamanca 37002, Spain.

Abstract

Motivation: Modern genomic technologies allow us to perform genome-wide analysis to find gene markers associated with the risk and survival in cancer patients. Accurate risk prediction and patient stratification based on robust gene signatures is a key path forward in personalized treatment and precision medicine. Several authors have proposed the identification of gene signatures to assign risk in patients with breast cancer (BRCA), and some of these signatures have been implemented within commercial platforms in the clinic, such as Oncotype and Prosigna. However, these platforms are black boxes in which the influence of selected genes as survival markers is unclear and where the risk scores provided cannot be clearly related to the standard clinicopathological tumor markers obtained by immunohistochemistry (IHC), which guide clinical and therapeutic decisions in breast cancer.

Results: Here, we present a framework to discover a robust list of gene expression markers associated with survival that can be biologically interpreted in terms of the three main biomolecular factors (IHC clinical markers: ER, PR and HER2) that define clinical outcome in BRCA. To test and ensure the reproducibility of the results, we compiled and analyzed two independent datasets with a large number of tumor samples (1024 and 879) that include full genome-wide expression profiles and survival data. Using these two cohorts, we obtained a robust subset of gene survival markers that correlate well with the major IHC clinical markers used in breast cancer. The geneset of survival markers that we identify (which includes 34 genes) significantly improves the risk prediction provided by the genesets included in the commercial platforms: Oncotype (16 genes) and Prosigna (50 genes, i.e. PAM50). Furthermore, some of the genes identified have recently been proposed in the literature as new prognostic markers and may deserve more attention in current clinical trials to improve breast cancer risk prediction.

Availability and implementation: All data integrated and analyzed in this research will be available on GitHub (https://github.com/jdelasrivas-lab/breastcancersurvsign), including the R scripts and protocols used for the analyses.

Supplementary information: Supplementary data are available at Bioinformatics Advances online.